About
Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases, specifically targeting unmet medical needs in immunology and hematology. The company boasts a robust pipeline of biologic drug candidates advancing through clinical stages, supported by a seasoned management team with strong industry expertise. Strategic collaborations strengthen Rallybio's capabilities in delivering transformative treatments, ultimately aiming to enhance patient outcomes. With a clear commitment to underserved therapeutic areas, Rallybio is well-positioned to make significant contributions to the healthcare sector while paving the way toward commercial success.
Advanced charting, extended hours trading, and free stock for new accounts.
Price data sourced from Polygon.io (previous trading day close). Fundamentals from Alpha Vantage. Insider trades from SEC EDGAR. Cached via Cloudflare KV.